TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04051996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: Glasdegib will be administered at the starting dose of 100 mg orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib
Description: Glasdegib will be administered at the starting dose of 100 mg orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered per local label and will be administered by IV infusion at a dose of 20 mg/m2/day for either 5 days or 10 days as determined by randomization. Each cycle will be every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine will be administered per local label and will be administered by IV infusion at a dose of 20 mg/m2/day for either 5 days or 10 days as determined by randomization. Each cycle will be every 28 days.
Study: NCT02163538

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: articulating Enseal
Description: Vessel-sealing device used for laparoscopic hysterectomy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure device
Description: Vessel-sealing device used for laparoscopic hysterectomy.
Study: NCT01488604

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymeric Nasal Spray
Description: Experimental nasal spray

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Nasal Spray
Description: Sham nasal spray
Study: NCT00894803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Description: IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA
Description: Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA
Description: Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.
Study: NCT04006288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Patients on aspirin and plavix will be randomized to either continue with aspirin and plavix or to switch to aspirin and rivaroxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: Patients on aspirin and prasugrel will be randomized to either continue with aspirin and prasugrel or to switch to aspirin and rivaroxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ticagrelor
Description: Patients on aspirin and ticagrelor will be randomized to either continue with aspirin and ticagrelor or to switch to aspirin and rivaroxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: all patients will remain on aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: all patients will remain on aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: all patients will remain on aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: all patients will remain on aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: all patients will remain on aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: all patients will remain on aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: Patients on DAPT will be randomized to either continue with DAPT or to switch to aspirin and rivaroxaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: Patients on DAPT will be randomized to either continue with DAPT or to switch to aspirin and rivaroxaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban
Description: Patients on DAPT will be randomized to either continue with DAPT or to switch to aspirin and rivaroxaban
Study: NCT01412996

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: single ACCESS laparoscopic cholecystectomy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SURGERY
Description: CONVENTIONAL LAPAROSCOPIC CGOLECYSTECTOMY
Study: NCT03101280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg (equivalent to an average body weight-based dose of 15 milligrams per kilogram \[mg/kg\]) will be administered by IV infusion once every 3 weeks, corresponding to a 21-day treatment cycle. Participants will receive atezolizumab starting on Cycle 1, Day 1. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg (equivalent to an average body weight-based dose of 15 milligrams per kilogram \[mg/kg\]) will be administered by IV infusion once every 3 weeks, corresponding to a 21-day treatment cycle. Participants will receive atezolizumab starting on Cycle 1, Day 1. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: The starting dosage level of rucaparib for Part 1 is 400 mg PO BID during a 21-day treatment cycle. During Part 1, the rucaparib doses were increased up to a maximum of 600 mg PO BID using a standard 3 + 3 dose escalation. RP2D was identified as 600 mg BID. During Part 2 of the study, rucaparib will be dosed at the RP2D determined in Part 1. Participants in Part 1 of the study will receive rucaparib starting on Cycle 1, Day 1. During Part 2, participants will receive rucaparib monotherapy during a 21-day run-in period. After completion of the rucaparib run-in period and the first on-treatment biopsy between Days 15 and 21 of the run-in period, participants will begin Cycle 1, Day 1 of the rucaparib. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: The starting dosage level of rucaparib for Part 1 is 400 mg PO BID during a 21-day treatment cycle. During Part 1, the rucaparib doses were increased up to a maximum of 600 mg PO BID using a standard 3 + 3 dose escalation. RP2D was identified as 600 mg BID. During Part 2 of the study, rucaparib will be dosed at the RP2D determined in Part 1. Participants in Part 1 of the study will receive rucaparib starting on Cycle 1, Day 1. During Part 2, participants will receive rucaparib monotherapy during a 21-day run-in period. After completion of the rucaparib run-in period and the first on-treatment biopsy between Days 15 and 21 of the run-in period, participants will begin Cycle 1, Day 1 of the rucaparib. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
Study: NCT04871906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching exercises
Description: Our interventions are home-based stretching exercises. The experimental group will receive 6 stretching exercises which stretch 20-30 seconds, relax for 10 seconds, and repeat 5 times for each side. It will take 25-30 minutes every day for continuous 8 weeks. Those include stretching of the deep front line, spiral line, superficial front line, lateral line, superficial back line, and plantar flexors. Designed concepts are the following three: 1) based on ''Anatomy- Train'' theory, 2) emphasize on movements of trunk and pelvis, and 3) stress on the stretching of lower extremities.
Study: NCT00965601

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Subjects randomized to the Active Arm will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
Study: NCT01651728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Tablet 20 mg once daily for 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily for 30 days
Study: NCT01821079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
Study: NCT03587376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atabecestat
Description: Blood samples will be collected from participants previously treated with atabecestat.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atabecestat
Description: Blood samples will be collected from participants previously treated with atabecestat.
Study: NCT04554784

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Patients' condition will be continue managed by pain specialists with regular follow-ups and continue patients' active concurrent pain treatment such as taking analgesics, physiotherapy, massage, chiropractor.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bowen
Description: Patients will be referred to Occupational therapist for Bowen Therapy. There will be a week washout period before the start of Bowen Therapy. During a week washout period and study period, patients can continue taking analgesia, but advised to stop the concurrent treatments which can affect the deep tissue such as massage, physiotherapy, and chiropractic to minimize the counteracting effect on the Bowen's action.~During a Bowen Therapy session, patients will lie relaxed on the examination couch wearing loosely fitting clothing or only the affected area being exposed. The therapist applies a series of gentle movements across the body. The gentle movements focus on a body of muscle, tendon or nerve and release tension through the nerve within the area. Each session will last for 30 minutes to an hour. After each session, the next appointment will be given to patients. The first four sessions will be scheduled on weekly basis, and the remaining four on biweekly session.
Study: NCT02641925

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omentum preserving
Description: The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed during gastrectomy with lymph node dissection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total omentectomy
Description: Whole omentum will be removed during gastrectomy with lymph node dissection.
Study: NCT00449696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gel-200
Description: Single intra-articular injection

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intra-articular injection
Study: NCT00711698

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: Patients in this arm will be treated with a bolus of narcotic followed by PCA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nurse-administered intermittent IV bolus opioid therapy (NAIBOD)
Description: In this arm patients will receive the current standard of care of IV bolus narcotic therapy
Study: NCT01205217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib 1000 mg orally once daily continuously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Part II (Week 13-24) Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week
Study: NCT02356458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Ibrutinib: p.o daily; Phase I: according to DL; Phase II: RP2D established in phase I~Maintenance therapy:~p.o daily: 560 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Combination therapy:~Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Injection of Bortezomib (s.c.), dose of 1.3 mg/m2 on day 1, 4, 8, 11
Study: NCT01026844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Taken orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Taken orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: Taken orally once a day
Study: NCT03322956

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physioterapy intervention
Description: In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physioterapy intervention
Description: In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).~The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®.
Study: NCT01446159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-573
Description: Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
Study: NCT02890797

Intervention type: RADIATION
Group type: OTHER
Intervention: radiology
Description: The investigators propose to performed a chest ultrasound in infants (\<24 months) admitted for bronchiolitis with an available chest X-ray
Study: NCT03631485

Intervention type: OTHER
Intervention: Exposure_having children with cancer
Description: No intervention. The exposure is having children with cancer.
Study: NCT04712188

Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal ultrasonography
Description: The ultrasonographic assesment will be used to examine the supraspinatus tendon thickness, the long head of the biceps brachii tendon thickness and acromio-humeral distance before and after wheelchair propelling test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal ultrasonography
Description: The ultrasonographic assesment will be used to examine the supraspinatus tendon thickness, the long head of the biceps brachii tendon thickness and acromio-humeral distance before and after wheelchair propelling test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal ultrasonography
Description: The ultrasonographic assesment will be used to examine the supraspinatus tendon thickness, the long head of the biceps brachii tendon thickness and acromio-humeral distance before and after wheelchair propelling test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Musculoskeletal ultrasonography
Description: The ultrasonographic assesment will be used to examine the supraspinatus tendon thickness, the long head of the biceps brachii tendon thickness and acromio-humeral distance before and after wheelchair propelling test.

Intervention type: OTHER
Intervention: Wheelchair propelling test
Description: Participants will use their own wheelchairs with their preferred stroke pattern for 20 minutes at a speed of 1 m / s on a motorized treadmill for a wheelchair propelling test. Wheelchair propelling videos will be recorded during the test. Shoulder kinematics will be analyzed using Kinovea motion analysis software and stoke pattern will be confirmed

Intervention type: OTHER
Intervention: Wheelchair propelling test
Description: Participants will use their own wheelchairs with their preferred stroke pattern for 20 minutes at a speed of 1 m / s on a motorized treadmill for a wheelchair propelling test. Wheelchair propelling videos will be recorded during the test. Shoulder kinematics will be analyzed using Kinovea motion analysis software and stoke pattern will be confirmed

Intervention type: OTHER
Intervention: Wheelchair propelling test
Description: Participants will use their own wheelchairs with their preferred stroke pattern for 20 minutes at a speed of 1 m / s on a motorized treadmill for a wheelchair propelling test. Wheelchair propelling videos will be recorded during the test. Shoulder kinematics will be analyzed using Kinovea motion analysis software and stoke pattern will be confirmed

Intervention type: OTHER
Intervention: Wheelchair propelling test
Description: Participants will use their own wheelchairs with their preferred stroke pattern for 20 minutes at a speed of 1 m / s on a motorized treadmill for a wheelchair propelling test. Wheelchair propelling videos will be recorded during the test. Shoulder kinematics will be analyzed using Kinovea motion analysis software and stoke pattern will be confirmed
Study: NCT04731636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thoracoabdominal aortic stent system
Description: Patients who meet all inclusion criteria and don't meet any exclusion criteria were implanted with thoracoabdominal aortic stent system.
Study: NCT03874546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: * Two clinicians will complete a questionnaire that analyses their perception of the patient's prognosis at Day1 and Day7.~* At 6 months, another clinician will establish the patient prognosis using Glasgow Outcome Scale and Glasgow outcome scale extended. This clinician must not know the patient's IMPACT score and prognosis established at Day 1 and Day 7. His evaluation will be compare to the patient's prognosis established previously (Day1 and Day7).
Study: NCT03523819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1002
Description: Dose levels will be escalated following a modified 3+3 dose escalation scheme

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1002
Description: Dose levels will be escalated following a modified 3+3 dose escalation scheme

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1003
Description: Fixed dose at 200mg in combination with CS1002 on a specified dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS1003
Description: Fixed dose at 200mg in combination with CS1002 on a specified dose level
Study: NCT03566602

Intervention type: DEVICE
Group type: OTHER
Intervention: Dura Sealant Patch
Description: Adjunctive bioresorbable patch